Synopsis Adenoviral Conjunctivitis is a common condition affecting a majority of the population but there are no approved medications for the treatment of adenoviral conjunctivitis. The present study aims to evaluate the efficacy/safety of an ophthalmic suspension of povidone-iodine (PVP-I) 0.6% and dexamethasone 0.1% in patients with acute adenoviral conjunctivitis. This week’s “ MED FACT ” discusses a clinical study from The American Journal of Ophthalmology, “ Randomized, Controlled, Phase 2 Trial of Povidone-Iodine/Dexamethasone Ophthalmic Suspension for Treatment of Adenoviral Conjunctivitis ”. Oct 2018.
Authors : Jay S. Pepose et.al. Key Takeaways: An ophthalmic suspension of PVP-I 0.6% and dexamethasone 0.1% is safe and well tolerated for the treatment of acute adenoviral conjunctivitis. Objective: To evaluate the efficacy/safety of povidone-iodine (PVP-I) 0.6% and dexamethasone…
